TP53 Mutations As Potential Prognostic Markers for Specific Cancers: Analysis of Data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2018 Dec 14

PMID 30542790

Citations 52

Authors

Victor D Li

Karen H Li

John T Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Mutations in the tumor suppressor gene TP53 are associated with a variety of cancers. Therefore, it is important to know the occurrence and prognostic effects of TP53 mutations in certain cancers.

Methods: Over 29,000 cases from the April 2016 release of the International Agency for Research on Cancer (IARC) TP53 Database were analyzed to determine the distribution of germline and somatic mutations in the TP53 gene. Subsequently, 7,893 cancer cases were compiled in cBioPortal for Cancer Genomics from the 33 most recent The Cancer Genome Atlas (TCGA) studies to determine the prevalence of TP53 mutations in cancers and their effects on survival and disease-free survival times.

Results: The data were analyzed, and it was found that the majority of TP53 mutations were missense and the major mutational hotspots were located at codons 248, 273, 175, and 245 in exons 4-8 for somatic mutations with the addition of codon 337 and other mutations in exons 9-10 for germline mutations. Out of 33 TGCA studies, the effects of TP53 mutations were statistically significant in nine cancers (lung adenocarcinoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, acute myeloid leukemia, clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, uterine endometrial carcinoma, and thymoma) for survival time and in five cancers (pancreatic adenocarcinoma, hepatocellular carcinoma, chromophobe RCC, acute myeloid leukemia, and thymoma) for disease-free survival time. It was also found that the most common p53 mutation in hepatocellular carcinomas (R249S) was a much better indicator for poor prognosis than TP53 mutations as a whole. In addition, in cases of ovarian serous cystadenocarcinoma, the co-occurrence of TP53 and BRCA mutations resulted in longer survival and disease-free survival times than the presence of neither TP53 nor BRCA mutations.

Conclusion: TP53 mutations are potential prognostic markers that can be used to further improve the accuracy of predicting survival and disease-free survival times of cancer patients.

Citing Articles

Establishment and verification of a prognostic signature associated with fatty acid metabolism in endometrial cancer.

Peng L, Sun R, Hao T, Mu Y, Zhang Q, Jiang J Mol Med Rep. 2025; 31(3).

PMID: 39886973 PMC: 11795235. DOI: 10.3892/mmr.2025.13444.

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review.

Zhang C, Yang C, Shi Q Cancer Manag Res. 2025; 17():65-82.

PMID: 39830995 PMC: 11742633. DOI: 10.2147/CMAR.S495006.

Prediction of prognosis, efficacy of lung adenocarcinoma by machine learning model based on immune and metabolic related genes.

Xue C, Dai Y, Li G, Zhang Y Discov Oncol. 2024; 15(1):778.

PMID: 39692796 PMC: 11655725. DOI: 10.1007/s12672-024-01515-x.

Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53.

Gong L, Xu D, Ni K, Li J, Mao W, Zhang B Adv Sci (Weinh). 2024; 12(4):e2402258.

PMID: 39629919 PMC: 11789598. DOI: 10.1002/advs.202402258.

Li-Fraumeni Syndrome: Narrative Review Through a Case Report with Ten Years of Primary Tumor Remission Associated with H387 07 Supplementation.

Amador-Gomez A, Aguiniga-Sanchez I, Mendoza-Nunez V, Cadena-Iniguez J, Romero-Lopez E, Santiago-Osorio E Int J Mol Sci. 2024; 25(21).

PMID: 39519030 PMC: 11546847. DOI: 10.3390/ijms252111477.

References

Zhu J, Zhang S, Jiang J, Chen X . Definition of the p53 functional domains necessary for inducing apoptosis. J Biol Chem. 2000; 275(51):39927-34. DOI: 10.1074/jbc.M005676200. View

Friedler A, Veprintsev D, Hansson L, Fersht A . Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem. 2003; 278(26):24108-12. DOI: 10.1074/jbc.M302458200. View

Kato S, Han S, Liu W, Otsuka K, Shibata H, Kanamaru R . Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003; 100(14):8424-9. PMC: 166245. DOI: 10.1073/pnas.1431692100. View

Edwards S, Hananeia L, Eccles M, Zhang Y, Braithwaite A . The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene. 2003; 22(29):4517-23. DOI: 10.1038/sj.onc.1206726. View

Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J . The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006; 12(4):1157-67. DOI: 10.1158/1078-0432.CCR-05-1029. View

Harms K, Chen X . The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. 2006; 13(6):890-7. DOI: 10.1038/sj.cdd.4401904. View

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian S, Hainaut P . Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28(6):622-9. DOI: 10.1002/humu.20495. View

Olivier M, Hollstein M, Hainaut P . TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2(1):a001008. PMC: 2827900. DOI: 10.1101/cshperspect.a001008. View

Rich J, Neely J, Paniello R, Voelker C, Nussenbaum B, Wang E . A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010; 143(3):331-6. PMC: 3932959. DOI: 10.1016/j.otohns.2010.05.007. View

10.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

11.

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

12.

. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417):519-25. PMC: 3466113. DOI: 10.1038/nature11404. View

13.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

14.

Salnikova L . Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database. Neuromolecular Med. 2014; 16(2):431-47. DOI: 10.1007/s12017-014-8290-1. View

15.

Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J . TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat. 2016; 37(9):865-76. DOI: 10.1002/humu.23035. View

16.

Kim Y, Cho M, Kim J, Kim S, Oh S, Lee K . Profiling cancer-associated genetic alterations and molecular classification of cancer in Korean gastric cancer patients. Oncotarget. 2017; 8(41):69888-69905. PMC: 5642524. DOI: 10.18632/oncotarget.19435. View

17.

Alidousty C, Baar T, Martelotto L, Heydt C, Wagener S, Fassunke J . Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations. J Pathol. 2018; 246(1):67-76. PMC: 6120547. DOI: 10.1002/path.5110. View

18.

Pavletich N, Chambers K, Pabo C . The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993; 7(12B):2556-64. DOI: 10.1101/gad.7.12b.2556. View

19.

Lomax M, Barnes D, Gilchrist R, Picksley S, Varley J, Camplejohn R . Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene. 1997; 14(15):1869-74. DOI: 10.1038/sj.onc.1201133. View